SUNHO
BIOPHARMACEUTICAL (CHINA) CO. LTD

Sunho Biologics, Inc.
盛禾生物控股有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2898)

REQUISITION FROM SHAREHOLDERS TO CONVENE EXTRAORDINARY GENERAL MEETING

The board (the "**Board**") of directors (the "**Directors**") of Sunho Biologics Inc. (the "**Company**") announces that, on August 6, 2026, the Board received a joint notice of requisition (the "**Requisition Notice**") from two shareholders of the Company (the "**Shareholders**"), namely, Huzhou Efung Ansheng Venture Capital Partnership (Limited Partnership) (湖州市倚鋒安盛創業投資合夥企業(有限合夥)) ("**Efung Ansheng**") and Huzhou Efung Anhe Venture Capital Partnership (Limited Partnership) (湖州市倚鋒安禾創業投資合夥企業(有限合夥)) ("**Efung Anhe**"), to convene an extraordinary general meeting ("**EGM**") for considering and, if thought fit, passing the following resolution:

1. "THAT Dr. XIA Long (夏龍) be appointed as a non-executive Director with effect upon passing of this ordinary resolution."

To the best knowledge of the Directors, after making reasonable enquiries, Efung Ansheng and Efung Anhe collectively hold an aggregate of 17,500,000 issued shares of the Company (the "**Shares**"), representing approximately 11.17% of the total issued share capital of the Company.

Pursuant to Article 17.6 of the articles of association of the Company (the "**Articles of Association**"), the Directors shall, within 21 days from the date of the deposit of the Requisition Notice, proceed to convene a general meeting. If the Directors do not within 21 days from the date of the deposit of the Shareholders' the Requisition Notice duly proceed to convene a general meeting to be held within a further 21 days, the requisitionists, or any of them representing more than one-half of the total voting rights of all of the requisitionists, may themselves convene a general meeting, but any meeting so convened shall be held no later than the day which falls three months after the expiration of the said 21 day period. As such, the Company will convene the EGM according to the Articles of Association.

CONTINUED SUSPENSION OF TRADING

Trading in the Shares on The Stock Exchange of Hong Kong Limited has been suspended with effect from 9:00 a.m. on April 1, 2026 and will continue to be suspended pending the publication of the 2025 annual results by the Company.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors of the Company are advised to seek advice from professional or financial advisers.

By order of the Board
Sunho Biologics, Inc.
Mr. ZHANG Feng
Chairman and executive Director

Hong Kong, August 7, 2026

As at the date of this announcement, the executive Directors are Mr. ZHANG Feng and Ms. JIANG Xiaoling; and the independent non-executive Directors are Mr. CHAN Heung Wing Anthony, Ms. FENG Lan and Mr. SHI Luwen.